Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$5.50
+1.5%
$4.57
$2.37
$5.72
$1.22B2.53780,549 shs994,162 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.23
+1.4%
$2.05
$1.04
$3.73
$335.64M1.182.17 million shs1.08 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.39
+4.2%
$24.06
$16.16
$31.53
$1.22B0.75218,752 shs469,142 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$16.33
+6.7%
$16.44
$7.93
$25.29
$1.36B0.721.62 million shs2.10 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
+1.48%+1.85%+22.77%+92.31%+79.74%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
+1.36%+3.72%+5.19%+22.53%-24.02%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+4.22%+12.35%+29.55%+77.14%+83.14%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+6.73%+10.04%+9.52%+21.05%+72.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CureVac N.V. stock logo
CVAC
CureVac
4.4976 of 5 stars
4.15.00.04.90.00.01.3
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.8222 of 5 stars
3.50.00.04.22.81.70.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.6762 of 5 stars
0.92.02.51.13.03.32.5
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.3236 of 5 stars
4.43.00.00.02.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8324.24% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.00124.22% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-22.27% Downside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.1496.83% Upside

Current Analyst Ratings Breakdown

Latest HRTX, TVTX, CVAC, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
7/1/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$30.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.13$0.89 per share6.21$3.36 per share1.64
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$144.29M2.36N/AN/A($0.22) per share-10.14
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.25$2.20 per share14.25$6.34 per share4.95
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M6.22N/AN/A$0.76 per share21.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.98N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7840.2414.950.502.68%30.51%6.89%8/27/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)

Latest HRTX, TVTX, CVAC, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.26N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01N/AN/AN/A$38.08 millionN/A
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.53%N/A61.54%N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A

Latest HRTX, TVTX, CVAC, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.40
1.76
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03

Institutional Ownership

CompanyInstitutional Ownership
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
5.86%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.62 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.08 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Travere Therapeutics Lowered by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

CureVac stock logo

CureVac NASDAQ:CVAC

$5.50 +0.08 (+1.48%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$5.44 -0.06 (-1.09%)
As of 07/9/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$2.23 +0.03 (+1.36%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$2.18 -0.04 (-2.02%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.39 +1.27 (+4.22%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$31.00 -0.39 (-1.24%)
As of 07/9/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$16.33 +1.03 (+6.73%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$16.32 0.00 (-0.03%)
As of 07/9/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.